Comparison of Bivalent and Monovalent mRNA Vaccine Boosters.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 37647855.
- Also identified by DOI 10.1093/cid/ciad519.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this cohort study conducted in Hong Kong where both bivalent and monovalent formulations of BNT162b2 were available, there were no significant differences in the mortality or hospitalization between those who received bivalent and monovalent mRNA as second boosters. Bivalent and monovalent mRNA boosters appear equally protective against clinical outcomes.
Medical subject headings
- mRNA Vaccines
- BNT162 Vaccine